Trial Breakthrough: Social media buzz centers on Moderna's personalized mRNA vaccine for melanoma, developed with Merck, achieving key endpoints in a late-stage trial. Analysts highlight how the therapy extends recurrence-free survival when paired with Keytruda. Observers note the use of AI to tailor neoantigens for individual patients as a pivotal advance.
Market Reaction: Shares of Moderna surged sharply following the announcement, with some participants describing the move as a potential re-rating of the company's long-term prospects. Discussions emphasize the shift from COVID-era focus to oncology applications. Commenters point to the data as validation of mRNA technology beyond initial uses.
Broader Context: The results have sparked debate on mRNA's role in future cancer treatments, with some viewing it as a milestone for personalized medicine. Sentiment remains charged with optimism about expanded applications. Participants underscore the milestone without speculating on valuation levels.
Note: This discussion summary was generated from an AI condensation of post data.
Moderna Insider Trading Activity
Moderna insiders have traded $MRNA stock on the open market 12 times in the past 6 months. Of those trades, 0 have been purchases and 12 have been sales.
Here’s a breakdown of recent trading of $MRNA stock by insiders over the last 6 months:
- STEPHANE BANCEL (Chief Executive Officer) has made 0 purchases and 4 sales selling 499,246 shares for an estimated $28,715,011.
- STEPHEN HOGE (President) has made 0 purchases and 4 sales selling 320,017 shares for an estimated $16,741,685.
- SHANNON THYME KLINGER (Chief Legal Officer) has made 0 purchases and 2 sales selling 17,356 shares for an estimated $899,596.
- NOUBAR AFEYAN sold 9,263 shares for an estimated $433,878
- ABBAS HUSSAIN sold 5,682 shares for an estimated $264,951
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Moderna Hedge Fund Activity
We have seen 382 institutional investors add shares of Moderna stock to their portfolio, and 390 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 6,187,867 shares (+13.5%) to their portfolio in Q2 2026, for an estimated $433,336,326
- D. E. SHAW & CO., INC. removed 5,157,808 shares (-99.5%) from their portfolio in Q2 2026, for an estimated $361,201,294
- PRICE T ROWE ASSOCIATES INC /MD/ added 4,850,982 shares (+656.8%) to their portfolio in Q2 2026, for an estimated $339,714,269
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 4,838,884 shares (+inf%) to their portfolio in Q2 2026, for an estimated $338,867,046
- CAPITAL WORLD INVESTORS added 3,579,302 shares (+19.1%) to their portfolio in Q2 2026, for an estimated $250,658,519
- ALYESKA INVESTMENT GROUP, L.P. removed 3,490,366 shares (-86.2%) from their portfolio in Q2 2026, for an estimated $244,430,330
- BAILLIE GIFFORD & CO removed 2,373,736 shares (-11.5%) from their portfolio in Q2 2026, for an estimated $166,232,732
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Moderna Analyst Ratings
Wall Street analysts have issued reports on $MRNA in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 02/23/2026
To track analyst ratings and price targets for Moderna, check out Quiver Quantitative's $MRNA forecast page.
Moderna Price Targets
Multiple analysts have issued price targets for $MRNA recently. We have seen 8 analysts offer price targets for $MRNA in the last 6 months, with a median target of $46.5.
Here are some recent targets:
- Matthew Harrison from Morgan Stanley set a target price of $39.0 on 07/08/2026
- Luca Issi from RBC Capital set a target price of $45.0 on 07/07/2026
- Dimple Gosai from B of A Securities set a target price of $38.0 on 07/07/2026
- Edward Tenthoff from Piper Sandler set a target price of $77.0 on 06/26/2026
- Salveen Richter from Goldman Sachs set a target price of $49.0 on 05/04/2026
- Cory Kasimov from Evercore ISI Group set a target price of $50.0 on 05/04/2026
- Eliana Merle from UBS set a target price of $45.0 on 05/04/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
